In cancer research, EPHB2 has been linked to DNA repair, stem cell characteristics, and epigenetic regulation, including DNA methylation and RNA modifications.[29–31] Moreover, EPHB2 is involved in immune responses and cancer pathways, with high expression associated with epithelial-mesenchymal transition activation in various cancers.[32,33] In SLE, the presence of anti-EPHB2 autoantibodies in 56% of serum samples suggests that EPHB2 is highly recognized in SLE patients, with a specificity of 95% and sensitivity of 35%.[34] This indicates its potential as a diagnostic tool for SLE. The gene discussed is EPHB2; the disease is systemic lupus erythematosus.